PUMA BIOTECHNOLOGY INC (PBYI) is a publicly traded Healthcare sector company. As of July 23, 2026, PBYI trades at $7.94 with a market cap of $400.58M and a P/E ratio of 15.91. PBYI moved +2.03% today. Year to date, PBYI is +34.62%; over the trailing twelve months it is +132.17%. Its 52-week range spans $2.58 to $8.75. Analyst consensus is neutral with an average price target of $5.00. Rallies surfaces PBYI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PBYI combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $7.94 |
| Market Cap | $400.58M |
| P/E Ratio | 15.91 |
| EPS | $0.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.75 |
| 52-Week Low | $2.58 |
| Volume | 177.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $227.18M |
| Net Income | $24.38M |
| Gross Margin | 74.46% |
1 analysts cover PBYI: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $5.00.